Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
Public health policies and alcohol-related liver disease.

JHEP reports : innovation in hepatology

Ventura-Cots M, Ballester-Ferré MP, Ravi S, Bataller R.
PMID: 32039391
JHEP Rep. 2019 Aug 08;1(5):403-413. doi: 10.1016/j.jhepr.2019.07.009. eCollection 2019 Nov.

Alcohol-related liver disease (ALD) represents a major public health problem worldwide. According to the World Health Organization, the highest levels of per capita alcohol consumption are observed in countries of the European Region. Alcohol consumption is also alarmingly increasing...

Cite
Ventura-Cots M, Ballester-Ferré MP, Ravi S, et al. Public health policies and alcohol-related liver disease. JHEP Rep. 2019;1(5):403-413doi: 10.1016/j.jhepr.2019.07.009.
Ventura-Cots, M., Ballester-Ferré, M. P., Ravi, S., & Bataller, R. (2019). Public health policies and alcohol-related liver disease. JHEP reports : innovation in hepatology, 1(5), 403-413. https://doi.org/10.1016/j.jhepr.2019.07.009
Ventura-Cots, Meritxell, et al. "Public health policies and alcohol-related liver disease." JHEP reports : innovation in hepatology vol. 1,5 (2019): 403-413. doi: https://doi.org/10.1016/j.jhepr.2019.07.009
Ventura-Cots M, Ballester-Ferré MP, Ravi S, Bataller R. Public health policies and alcohol-related liver disease. JHEP Rep. 2019 Aug 08;1(5):403-413. doi: 10.1016/j.jhepr.2019.07.009. eCollection 2019 Nov. PMID: 32039391; PMCID: PMC7005647.
Copy Download .nbib Format: NLM
Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Parker R, Cabezas J, Altamirano J, Arab JP, Ventura-Cots M, Sinha A, Dhanda A, Arrese M, McCune CA, Rowe IA, Schnabl B, Mathurin P, Shawcross D, Abraldes JG, Lucey MR, Garcia-Tsao G, Verna E, Brown RS, Bosques-Padilla F, Vargas V, Louvet A, Holt AP, Bataller R.
PMID: 33516950
Clin Gastroenterol Hepatol. 2022 Feb;20(2):e289-e297. doi: 10.1016/j.cgh.2021.01.042. Epub 2021 Jan 28.

BACKGROUND AND AIMS: Alcoholic hepatitis (AH) is a severe condition with poor short-term prognosis. Specific treatment with corticosteroids slightly improves short-term survival but is associated with infection and is not used in many centers. A reliable method to identify...

Cite
Parker R, Cabezas J, Altamirano J, et al. Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2021;20(2):e289-e297doi: 10.1016/j.cgh.2021.01.042.
Parker, R., Cabezas, J., Altamirano, J., Arab, J. P., Ventura-Cots, M., Sinha, A., Dhanda, A., Arrese, M., McCune, C. A., Rowe, I. A., Schnabl, B., Mathurin, P., Shawcross, D., Abraldes, J. G., Lucey, M. R., Garcia-Tsao, G., Verna, E., Brown, R. S., Bosques-Padilla, F., Vargas, V., Louvet, A., Holt, A. P., & Bataller, R. (2022). Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 20(2), e289-e297. https://doi.org/10.1016/j.cgh.2021.01.042
Parker, Richard, et al. "Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. 20,2 (2022): e289-e297. doi: https://doi.org/10.1016/j.cgh.2021.01.042
Parker R, Cabezas J, Altamirano J, Arab JP, Ventura-Cots M, Sinha A, Dhanda A, Arrese M, McCune CA, Rowe IA, Schnabl B, Mathurin P, Shawcross D, Abraldes JG, Lucey MR, Garcia-Tsao G, Verna E, Brown RS, Bosques-Padilla F, Vargas V, Louvet A, Holt AP, Bataller R. Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2022 Feb;20(2):e289-e297. doi: 10.1016/j.cgh.2021.01.042. Epub 2021 Jan 28. PMID: 33516950.
Copy Download .nbib Format: NLM
Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients.

Therapeutic advances in gastroenterology

Ventura-Cots M, Concepción M, Arranz JA, Simón-Talero M, Torrens M, Blanco-Grau A, Fuentes I, Suñé P, Alvarado-Tapias E, Gely C, Roman E, Mínguez B, Soriano G, Genescà J, Córdoba J.
PMID: 27803737
Therap Adv Gastroenterol. 2016 Nov;9(6):823-835. doi: 10.1177/1756283X16658252. Epub 2016 Jul 26.

BACKGROUND: Ornithine phenylacetate (OP) has been proven effective in lowering ammonia plasma levels in animals, and to be well tolerated in cirrhotic patients. A trial to assess OP efficacy in lowering plasma ammonia levels METHODS: A total of 38...

Cite
Ventura-Cots M, Concepción M, Arranz JA, et al. Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients. Therap Adv Gastroenterol. 2016;9(6):823-835doi: 10.1177/1756283X16658252.
Ventura-Cots, M., Concepción, M., Arranz, J. A., Simón-Talero, M., Torrens, M., Blanco-Grau, A., Fuentes, I., Suñé, P., Alvarado-Tapias, E., Gely, C., Roman, E., Mínguez, B., Soriano, G., Genescà, J., & Córdoba, J. (2016). Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients. Therapeutic advances in gastroenterology, 9(6), 823-835. https://doi.org/10.1177/1756283X16658252
Ventura-Cots, Meritxell, et al. "Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients." Therapeutic advances in gastroenterology vol. 9,6 (2016): 823-835. doi: https://doi.org/10.1177/1756283X16658252
Ventura-Cots M, Concepción M, Arranz JA, Simón-Talero M, Torrens M, Blanco-Grau A, Fuentes I, Suñé P, Alvarado-Tapias E, Gely C, Roman E, Mínguez B, Soriano G, Genescà J, Córdoba J. Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients. Therap Adv Gastroenterol. 2016 Nov;9(6):823-835. doi: 10.1177/1756283X16658252. Epub 2016 Jul 26. PMID: 27803737; PMCID: PMC5076769.
Copy Download .nbib Format: NLM
Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis.

Journal of clinical medicine

Ventura-Cots M, Simón-Talero M, Poca M, Ariza X, Masnou H, Sanchez J, Llop E, Cañete N, Martín-Llahí M, Amador A, Martínez J, Clemente-Sanchez A, Puente A, Torrens M, Alvarado-Tapias E, Napoleone L, Miquel-Planas M, Ardèvol A, Casas Rodrigo M, Calleja JL, Solé C, Soriano G, Genescà J.
PMID: 34768404
J Clin Med. 2021 Oct 23;10(21). doi: 10.3390/jcm10214885.

No therapies have been proven to increase survival after a hepatic encephalopathy (HE) episode. We hypothesize that two doses of albumin could improve 90-day survival rates after a HE episode.METHODS: (1) A randomized double-blind, placebo-controlled trial (BETA) was conducted...

Cite
Ventura-Cots M, Simón-Talero M, Poca M, et al. Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis. J Clin Med. 2021;10(21)doi: 10.3390/jcm10214885.
Ventura-Cots, M., Simón-Talero, M., Poca, M., Ariza, X., Masnou, H., Sanchez, J., Llop, E., Cañete, N., Martín-Llahí, M., Amador, A., Martínez, J., Clemente-Sanchez, A., Puente, A., Torrens, M., Alvarado-Tapias, E., Napoleone, L., Miquel-Planas, M., Ardèvol, A., Casas Rodrigo, M., Calleja, J. L., Solé, C., Soriano, G., & Genescà, J. (2021). Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis. Journal of clinical medicine, 10(21), . https://doi.org/10.3390/jcm10214885
Ventura-Cots, Meritxell, et al. "Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis." Journal of clinical medicine vol. 10,21 (2021). doi: https://doi.org/10.3390/jcm10214885
Ventura-Cots M, Simón-Talero M, Poca M, Ariza X, Masnou H, Sanchez J, Llop E, Cañete N, Martín-Llahí M, Amador A, Martínez J, Clemente-Sanchez A, Puente A, Torrens M, Alvarado-Tapias E, Napoleone L, Miquel-Planas M, Ardèvol A, Casas Rodrigo M, Calleja JL, Solé C, Soriano G, Genescà J. Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis. J Clin Med. 2021 Oct 23;10(21). doi: 10.3390/jcm10214885. PMID: 34768404; PMCID: PMC8584661.
Copy Download .nbib Format: NLM
Role of MIF in coordinated expression of hepatic chemokines in patients with alcohol-associated hepatitis.

JCI insight

Poulsen KL, Fan X, Kibler CD, Huang E, Wu X, McMullen MR, Leng L, Bucala R, Ventura-Cots M, Argemi J, Bataller R, Nagy LE.
PMID: 33945507
JCI Insight. 2021 Jun 08;6(11). doi: 10.1172/jci.insight.141420.

The chemokine system of ligands and receptors is implicated in the progression of alcohol-associated hepatitis (AH). Finding upstream regulators could lead to novel therapies. This study involved coordinated expression of chemokines in livers of healthy controls (HC) and patients...

Cite
Poulsen KL, Fan X, Kibler CD, et al. Role of MIF in coordinated expression of hepatic chemokines in patients with alcohol-associated hepatitis. JCI Insight. 2021;6(11)doi: 10.1172/jci.insight.141420.
Poulsen, K. L., Fan, X., Kibler, C. D., Huang, E., Wu, X., McMullen, M. R., Leng, L., Bucala, R., Ventura-Cots, M., Argemi, J., Bataller, R., & Nagy, L. E. (2021). Role of MIF in coordinated expression of hepatic chemokines in patients with alcohol-associated hepatitis. JCI insight, 6(11), . https://doi.org/10.1172/jci.insight.141420
Poulsen, Kyle L, et al. "Role of MIF in coordinated expression of hepatic chemokines in patients with alcohol-associated hepatitis." JCI insight vol. 6,11 (2021). doi: https://doi.org/10.1172/jci.insight.141420
Poulsen KL, Fan X, Kibler CD, Huang E, Wu X, McMullen MR, Leng L, Bucala R, Ventura-Cots M, Argemi J, Bataller R, Nagy LE. Role of MIF in coordinated expression of hepatic chemokines in patients with alcohol-associated hepatitis. JCI Insight. 2021 Jun 08;6(11). doi: 10.1172/jci.insight.141420. PMID: 33945507; PMCID: PMC8262327.
Copy Download .nbib Format: NLM
Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study.

Journal of hepatology

Arab JP, Díaz LA, Baeza N, Idalsoaga F, Fuentes-López E, Arnold J, Ramírez CA, Morales-Arraez D, Ventura-Cots M, Alvarado-Tapias E, Zhang W, Clark V, Simonetto D, Ahn JC, Buryska S, Mehta TI, Stefanescu H, Horhat A, Bumbu A, Dunn W, Attar B, Agrawal R, Haque ZS, Majeed M, Cabezas J, García-Carrera I, Parker R, Cuyàs B, Poca M, Soriano G, Sarin SK, Maiwall R, Jalal PK, Abdulsada S, Higuera-de la Tijera MF, Kulkarni AV, Rao PN, Guerra Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko KR, Cairo F, de Sousa Coelho M, Romero GA, Pollarsky FD, Restrepo JC, Castro-Sanchez S, Toro LG, Yaquich P, Mendizabal M, Garrido ML, Narvaez A, Bessone F, Marcelo JS, Piombino D, Dirchwolf M, Arancibia JP, Altamirano J, Kim W, Araujo RC, Rojo AD, Vargas V, Rautou PE, Issoufaly T, Zamarripa F, Torre A, Lucey MR, Mathurin P, Louvet A, García-Tsao G, González JA, Verna E, Brown RS, Roblero JP, Abraldes JG, Arrese M, Shah VH, Kamath PS, Singal AK, Bataller R.
PMID: 34166722
J Hepatol. 2021 Nov;75(5):1026-1033. doi: 10.1016/j.jhep.2021.06.019. Epub 2021 Jun 21.

BACKGROUND & AIMS: Corticosteroids are the only effective therapy for severe alcohol-associated hepatitis (AH), defined by a model for end-stage liver disease (MELD) score >20. However, there are patients who may be too sick to benefit from therapy. Herein,...

Cite
Arab JP, Díaz LA, Baeza N, et al. Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. J Hepatol. 2021;75(5):1026-1033doi: 10.1016/j.jhep.2021.06.019.
Arab, J. P., Díaz, L. A., Baeza, N., Idalsoaga, F., Fuentes-López, E., Arnold, J., Ramírez, C. A., Morales-Arraez, D., Ventura-Cots, M., Alvarado-Tapias, E., Zhang, W., Clark, V., Simonetto, D., Ahn, J. C., Buryska, S., Mehta, T. I., Stefanescu, H., Horhat, A., Bumbu, A., Dunn, W., Attar, B., Agrawal, R., Haque, Z. S., Majeed, M., Cabezas, J., García-Carrera, I., Parker, R., Cuyàs, B., Poca, M., Soriano, G., Sarin, S. K., Maiwall, R., Jalal, P. K., Abdulsada, S., Higuera-de la Tijera, M. F., Kulkarni, A. V., Rao, P. N., Guerra Salazar, P., Skladaný, L., Bystrianska, N., Prado, V., Clemente-Sanchez, A., Rincón, D., Haider, T., Chacko, K. R., Cairo, F., de Sousa Coelho, M., Romero, G. A., Pollarsky, F. D., Restrepo, J. C., Castro-Sanchez, S., Toro, L. G., Yaquich, P., Mendizabal, M., Garrido, M. L., Narvaez, A., Bessone, F., Marcelo, J. S., Piombino, D., Dirchwolf, M., Arancibia, J. P., Altamirano, J., Kim, W., Araujo, R. C., Rojo, A. D., Vargas, V., Rautou, P. E., Issoufaly, T., Zamarripa, F., Torre, A., Lucey, M. R., Mathurin, P., Louvet, A., García-Tsao, G., González, J. A., Verna, E., Brown, R. S., Roblero, J. P., Abraldes, J. G., Arrese, M., Shah, V. H., Kamath, P. S., Singal, A. K., & Bataller, R. (2021). Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. Journal of hepatology, 75(5), 1026-1033. https://doi.org/10.1016/j.jhep.2021.06.019
Arab, Juan Pablo, et al. "Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study." Journal of hepatology vol. 75,5 (2021): 1026-1033. doi: https://doi.org/10.1016/j.jhep.2021.06.019
Arab JP, Díaz LA, Baeza N, Idalsoaga F, Fuentes-López E, Arnold J, Ramírez CA, Morales-Arraez D, Ventura-Cots M, Alvarado-Tapias E, Zhang W, Clark V, Simonetto D, Ahn JC, Buryska S, Mehta TI, Stefanescu H, Horhat A, Bumbu A, Dunn W, Attar B, Agrawal R, Haque ZS, Majeed M, Cabezas J, García-Carrera I, Parker R, Cuyàs B, Poca M, Soriano G, Sarin SK, Maiwall R, Jalal PK, Abdulsada S, Higuera-de la Tijera MF, Kulkarni AV, Rao PN, Guerra Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko KR, Cairo F, de Sousa Coelho M, Romero GA, Pollarsky FD, Restrepo JC, Castro-Sanchez S, Toro LG, Yaquich P, Mendizabal M, Garrido ML, Narvaez A, Bessone F, Marcelo JS, Piombino D, Dirchwolf M, Arancibia JP, Altamirano J, Kim W, Araujo RC, Rojo AD, Vargas V, Rautou PE, Issoufaly T, Zamarripa F, Torre A, Lucey MR, Mathurin P, Louvet A, García-Tsao G, González JA, Verna E, Brown RS, Roblero JP, Abraldes JG, Arrese M, Shah VH, Kamath PS, Singal AK, Bataller R. Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. J Hepatol. 2021 Nov;75(5):1026-1033. doi: 10.1016/j.jhep.2021.06.019. Epub 2021 Jun 21. PMID: 34166722.
Copy Download .nbib Format: NLM
Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals.

Therapeutic advances in gastroenterology

Pons M, Santos B, Simón-Talero M, Ventura-Cots M, Riveiro-Barciela M, Esteban R, Augustin S, Genescà J.
PMID: 28835776
Therap Adv Gastroenterol. 2017 Aug;10(8):619-629. doi: 10.1177/1756283X17715198. Epub 2017 Jun 27.

BACKGROUND: We aimed to investigate the early changes in liver and spleen stiffness measurement (LSM, SSM) in hepatitis C virus (HCV) patients with compensated advanced chronic liver disease (cACLD) treated with new antivirals (DAA) to elucidate factors determining the...

Cite
Pons M, Santos B, Simón-Talero M, et al. Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals. Therap Adv Gastroenterol. 2017;10(8):619-629doi: 10.1177/1756283X17715198.
Pons, M., Santos, B., Simón-Talero, M., Ventura-Cots, M., Riveiro-Barciela, M., Esteban, R., Augustin, S., & Genescà, J. (2017). Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals. Therapeutic advances in gastroenterology, 10(8), 619-629. https://doi.org/10.1177/1756283X17715198
Pons, Mònica, et al. "Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals." Therapeutic advances in gastroenterology vol. 10,8 (2017): 619-629. doi: https://doi.org/10.1177/1756283X17715198
Pons M, Santos B, Simón-Talero M, Ventura-Cots M, Riveiro-Barciela M, Esteban R, Augustin S, Genescà J. Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals. Therap Adv Gastroenterol. 2017 Aug;10(8):619-629. doi: 10.1177/1756283X17715198. Epub 2017 Jun 27. PMID: 28835776; PMCID: PMC5557188.
Copy Download .nbib Format: NLM
Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients.

Therapeutic advances in gastroenterology

Ventura-Cots M, Carmona I, Moreno C, Ampuero J, Simón-Talero M, Sanpedro F, Les I, Romero-Gómez M, Genescà J.
PMID: 29383024
Therap Adv Gastroenterol. 2017 Nov 26;11:1756283X17743419. doi: 10.1177/1756283X17743419. eCollection 2018.

BACKGROUND: Episodes of hepatic encephalopathy (HE) have been related to low survival rate. However, the relation between its clinical evolution and mortality has not been assessed.METHODS: A retrospective analysis of 245 cirrhotic patients admitted for an acute episode of...

Cite
Ventura-Cots M, Carmona I, Moreno C, et al. Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. Therap Adv Gastroenterol. 2017;11:1756283X17743419doi: 10.1177/1756283X17743419.
Ventura-Cots, M., Carmona, I., Moreno, C., Ampuero, J., Simón-Talero, M., Sanpedro, F., Les, I., Romero-Gómez, M., & Genescà, J. (2018). Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. Therapeutic advances in gastroenterology, 111756283X17743419. https://doi.org/10.1177/1756283X17743419
Ventura-Cots, Meritxell, et al. "Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients." Therapeutic advances in gastroenterology vol. 11 (2018): 1756283X17743419. doi: https://doi.org/10.1177/1756283X17743419
Ventura-Cots M, Carmona I, Moreno C, Ampuero J, Simón-Talero M, Sanpedro F, Les I, Romero-Gómez M, Genescà J. Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. Therap Adv Gastroenterol. 2017 Nov 26;11:1756283X17743419. doi: 10.1177/1756283X17743419. eCollection 2018. PMID: 29383024; PMCID: PMC5784576.
Copy Download .nbib Format: NLM
Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis.

Hepatology (Baltimore, Md.)

Hu K, Perez-Matos MC, Argemi J, Vilar-Gomez E, Shalaurova I, Bullitt E, Landeen L, Sugahara G, Deng H, Mathur K, Tran S, Cai H, He H, Yalcin Y, Vieira Barbosa J, Ventura-Cots M, Marx K, Gad AP, Niezen S, Izunza Barba S, Ang LH, Popov YV, Fricker Z, Lai M, Curry M, Afdhal N, Szabo G, Mukamal KJ, Sanyal AJ, Otvos JD, Malik R, Saito T, Connelly MA, Chalasani NP, Bataller R, Jiang ZG.
PMID: 34662439
Hepatology. 2021 Oct 18; doi: 10.1002/hep.32203. Epub 2021 Oct 18.

BACKGROUND AND AIMS: Lipoprotein Z (LP-Z) is an abnormal free cholesterol (FC)-enriched LDL-like particle discovered from patients with cholestatic liver disease. This study aims to define the diagnostic value of LP-Z in alcohol-associated hepatitis (AH) and interrogate the biology...

Cite
Hu K, Perez-Matos MC, Argemi J, et al. Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis. Hepatology. 2021;doi: 10.1002/hep.32203.
Hu, K., Perez-Matos, M. C., Argemi, J., Vilar-Gomez, E., Shalaurova, I., Bullitt, E., Landeen, L., Sugahara, G., Deng, H., Mathur, K., Tran, S., Cai, H., He, H., Yalcin, Y., Vieira Barbosa, J., Ventura-Cots, M., Marx, K., Gad, A. P., Niezen, S., Izunza Barba, S., Ang, L. H., Popov, Y. V., Fricker, Z., Lai, M., Curry, M., Afdhal, N., Szabo, G., Mukamal, K. J., Sanyal, A. J., Otvos, J. D., Malik, R., Saito, T., Connelly, M. A., Chalasani, N. P., Bataller, R., & Jiang, Z. G. (2021). Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis. Hepatology (Baltimore, Md.), . https://doi.org/10.1002/hep.32203
Hu, Kunpeng, et al. "Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis." Hepatology (Baltimore, Md.) vol. (2021). doi: https://doi.org/10.1002/hep.32203
Hu K, Perez-Matos MC, Argemi J, Vilar-Gomez E, Shalaurova I, Bullitt E, Landeen L, Sugahara G, Deng H, Mathur K, Tran S, Cai H, He H, Yalcin Y, Vieira Barbosa J, Ventura-Cots M, Marx K, Gad AP, Niezen S, Izunza Barba S, Ang LH, Popov YV, Fricker Z, Lai M, Curry M, Afdhal N, Szabo G, Mukamal KJ, Sanyal AJ, Otvos JD, Malik R, Saito T, Connelly MA, Chalasani NP, Bataller R, Jiang ZG. Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis. Hepatology. 2021 Oct 18; doi: 10.1002/hep.32203. Epub 2021 Oct 18. PMID: 34662439.
Copy Download .nbib Format: NLM
The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study.

The American journal of gastroenterology

Morales-Arráez D, Ventura-Cots M, Altamirano J, Abraldes JG, Cruz-Lemini M, Thursz MR, Atkinson SR, Sarin SK, Kim W, Chavez-Araujo R, Higuera-de la Tijera MF, Singal AK, Shah VH, Kamath PS, Duarte-Rojo A, Charles EA, Vargas V, Jager M, Rautou PE, Rincon D, Zamarripa F, Restrepo-Gutiérrez JC, Torre A, Lucey MR, Arab JP, Mathurin P, Louvet A, García-Tsao G, González JA, Verna EC, Brown RS, Argemi J, Fernández-Carillo C, Clemente A, Alvarado-Tapias E, Forrest E, Allison M, Bataller R.
PMID: 34962498
Am J Gastroenterol. 2021 Dec 28; doi: 10.14309/ajg.0000000000001596. Epub 2021 Dec 28.

INTRODUCTION: Several scoring systems predict mortality in alcohol-associated hepatitis (AH), including the Maddrey discriminant function (mDF) and model for end-stage liver disease (MELD) score developed in the United States, Glasgow alcoholic hepatitis score in the United Kingdom, and age,...

Cite
Morales-Arráez D, Ventura-Cots M, Altamirano J, et al. The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study. Am J Gastroenterol. 2021;doi: 10.14309/ajg.0000000000001596.
Morales-Arráez, D., Ventura-Cots, M., Altamirano, J., Abraldes, J. G., Cruz-Lemini, M., Thursz, M. R., Atkinson, S. R., Sarin, S. K., Kim, W., Chavez-Araujo, R., Higuera-de la Tijera, M. F., Singal, A. K., Shah, V. H., Kamath, P. S., Duarte-Rojo, A., Charles, E. A., Vargas, V., Jager, M., Rautou, P. E., Rincon, D., Zamarripa, F., Restrepo-Gutiérrez, J. C., Torre, A., Lucey, M. R., Arab, J. P., Mathurin, P., Louvet, A., García-Tsao, G., González, J. A., Verna, E. C., Brown, R. S., Argemi, J., Fernández-Carillo, C., Clemente, A., Alvarado-Tapias, E., Forrest, E., Allison, M., & Bataller, R. (2021). The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study. The American journal of gastroenterology, . https://doi.org/10.14309/ajg.0000000000001596
Morales-Arráez, D, et al. "The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study." The American journal of gastroenterology vol. (2021). doi: https://doi.org/10.14309/ajg.0000000000001596
Morales-Arráez D, Ventura-Cots M, Altamirano J, Abraldes JG, Cruz-Lemini M, Thursz MR, Atkinson SR, Sarin SK, Kim W, Chavez-Araujo R, Higuera-de la Tijera MF, Singal AK, Shah VH, Kamath PS, Duarte-Rojo A, Charles EA, Vargas V, Jager M, Rautou PE, Rincon D, Zamarripa F, Restrepo-Gutiérrez JC, Torre A, Lucey MR, Arab JP, Mathurin P, Louvet A, García-Tsao G, González JA, Verna EC, Brown RS, Argemi J, Fernández-Carillo C, Clemente A, Alvarado-Tapias E, Forrest E, Allison M, Bataller R. The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study. Am J Gastroenterol. 2021 Dec 28; doi: 10.14309/ajg.0000000000001596. Epub 2021 Dec 28. PMID: 34962498.
Copy Download .nbib Format: NLM
Clinical, histological and molecular profiling of different stages of alcohol-related liver disease.

Gut

Ventura-Cots M, Argemi J, Jones PD, Lackner C, El Hag M, Abraldes JG, Alvarado E, Clemente A, Ravi S, Alves A, Alboraie M, Altamirano J, Barace S, Bosques F, Brown R, Caballeria J, Cabezas J, Carvalhana S, Cortez-Pinto H, Costa A, Degré D, Fernandez-Carillo C, Ganne-Carrie N, Garcia-Tsao G, Genesca J, Koskinas J, Lanthier N, Louvet A, Lozano JJ, Lucey MR, Masson S, Mathurin P, Mendez-Sanchez N, Miquel R, Moreno C, Mounajjed T, Odena G, Kim W, Sancho-Bru P, Warren Sands R, Szafranska J, Verset L, Schnabl B, Sempoux C, Shah V, Shawcross DL, Stauber RE, Straub BK, Verna E, Tiniakos D, Trépo E, Vargas V, Villanueva C, Woosley JT, Ziol M, Mueller S, Stärkel P, Bataller R.
PMID: 34992134
Gut. 2022 Jan 06; doi: 10.1136/gutjnl-2021-324295. Epub 2022 Jan 06.

OBJECTIVE: Alcohol-related liver disease (ALD) ranges from never-decompensated ALD (ndALD) to the life-threatening decompensated phenotype, known as alcohol-related hepatitis (AH). A multidimensional study of the clinical, histological and molecular features of these subtypes is lacking.DESIGN: Two large cohorts of...

Cite
Ventura-Cots M, Argemi J, Jones PD, et al. Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. Gut. 2022;doi: 10.1136/gutjnl-2021-324295.
Ventura-Cots, M., Argemi, J., Jones, P. D., Lackner, C., El Hag, M., Abraldes, J. G., Alvarado, E., Clemente, A., Ravi, S., Alves, A., Alboraie, M., Altamirano, J., Barace, S., Bosques, F., Brown, R., Caballeria, J., Cabezas, J., Carvalhana, S., Cortez-Pinto, H., Costa, A., Degré, D., Fernandez-Carillo, C., Ganne-Carrie, N., Garcia-Tsao, G., Genesca, J., Koskinas, J., Lanthier, N., Louvet, A., Lozano, J. J., Lucey, M. R., Masson, S., Mathurin, P., Mendez-Sanchez, N., Miquel, R., Moreno, C., Mounajjed, T., Odena, G., Kim, W., Sancho-Bru, P., Warren Sands, R., Szafranska, J., Verset, L., Schnabl, B., Sempoux, C., Shah, V., Shawcross, D. L., Stauber, R. E., Straub, B. K., Verna, E., Tiniakos, D., Trépo, E., Vargas, V., Villanueva, C., Woosley, J. T., Ziol, M., Mueller, S., Stärkel, P., & Bataller, R. (2022). Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. Gut, . https://doi.org/10.1136/gutjnl-2021-324295
Ventura-Cots, Meritxell, et al. "Clinical, histological and molecular profiling of different stages of alcohol-related liver disease." Gut vol. (2022). doi: https://doi.org/10.1136/gutjnl-2021-324295
Ventura-Cots M, Argemi J, Jones PD, Lackner C, El Hag M, Abraldes JG, Alvarado E, Clemente A, Ravi S, Alves A, Alboraie M, Altamirano J, Barace S, Bosques F, Brown R, Caballeria J, Cabezas J, Carvalhana S, Cortez-Pinto H, Costa A, Degré D, Fernandez-Carillo C, Ganne-Carrie N, Garcia-Tsao G, Genesca J, Koskinas J, Lanthier N, Louvet A, Lozano JJ, Lucey MR, Masson S, Mathurin P, Mendez-Sanchez N, Miquel R, Moreno C, Mounajjed T, Odena G, Kim W, Sancho-Bru P, Warren Sands R, Szafranska J, Verset L, Schnabl B, Sempoux C, Shah V, Shawcross DL, Stauber RE, Straub BK, Verna E, Tiniakos D, Trépo E, Vargas V, Villanueva C, Woosley JT, Ziol M, Mueller S, Stärkel P, Bataller R. Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. Gut. 2022 Jan 06; doi: 10.1136/gutjnl-2021-324295. Epub 2022 Jan 06. PMID: 34992134.
Copy Download .nbib Format: NLM
Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Parker R, Cabezas J, Altamirano J, Arab JP, Ventura-Cots M, Sinha A, Dhanda A, Arrese M, McCune CA, Rowe IA, Schnabl B, Mathurin P, Shawcross D, Abraldes JG, Lucey MR, Garcia-Tsao G, Verna E, Brown RS, Bosques-Padilla F, Vargas V, Louvet A, Holt AP, Bataller R.
PMID: 33516950
Clin Gastroenterol Hepatol. 2021 Jan 28; doi: 10.1016/j.cgh.2021.01.042. Epub 2021 Jan 28.

BACKGROUND AND AIMS: Alcoholic hepatitis (AH) is a severe condition with poor short-term prognosis. Specific treatment with corticosteroids slightly improves short-term survival but is associated with infection and is not used in many centers. A reliable method to identify...

Cite
Parker R, Cabezas J, Altamirano J, et al. Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2021;doi: 10.1016/j.cgh.2021.01.042.
Parker, R., Cabezas, J., Altamirano, J., Arab, J. P., Ventura-Cots, M., Sinha, A., Dhanda, A., Arrese, M., McCune, C. A., Rowe, I. A., Schnabl, B., Mathurin, P., Shawcross, D., Abraldes, J. G., Lucey, M. R., Garcia-Tsao, G., Verna, E., Brown, R. S., Bosques-Padilla, F., Vargas, V., Louvet, A., Holt, A. P., & Bataller, R. (2021). Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, . https://doi.org/10.1016/j.cgh.2021.01.042
Parker, Richard, et al. "Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. (2021). doi: https://doi.org/10.1016/j.cgh.2021.01.042
Parker R, Cabezas J, Altamirano J, Arab JP, Ventura-Cots M, Sinha A, Dhanda A, Arrese M, McCune CA, Rowe IA, Schnabl B, Mathurin P, Shawcross D, Abraldes JG, Lucey MR, Garcia-Tsao G, Verna E, Brown RS, Bosques-Padilla F, Vargas V, Louvet A, Holt AP, Bataller R. Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2021 Jan 28; doi: 10.1016/j.cgh.2021.01.042. Epub 2021 Jan 28. PMID: 33516950.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries